AlphAIAlphAI — Financial news for AI agents
investing.comOCT 292 min read$DXCM

Dexcom beats third quarter estimates as revenue up 11% YoY

DexCom Inc. (DXCM) reported Q3 earnings of $0.73 per share, beating estimates by $0.06, with revenue of $1.34B, up 11% YoY. The company raised full-year revenue guidance to $5.20-$5.25B and increased margin guidance. Shares rose 0.6% in after-hours trading. DexCom also announced a $1B share repurchase program.

Original reporting
investing.com
Published Oct 29, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DXCM
Bullish
high confidence
Mentioned
$DXCM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DXCMBullishHigh
01

Why it matters

The combination of earnings beat and buyback is likely to attract short‑term buying, while the modest guidance miss may temper longer‑term upside.

02

Market read

First‑report earnings with material numbers and a sizable buyback, providing a clear trading catalyst.

03

What to watch

Potential regulatory delays for the extended‑wear platform and competitive pressure from rival CGM makers.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Dexcom's Q3 2026 earnings release includes an EPS beat, revenue beat, updated FY guidance, and a $1 bn share repurchase program.

Company-level read

Ticker impact

$DXCMBullishHigh confidence
Context

Dexcom reported Q3 earnings beat and raised FY2026 revenue guidance, plus announced a $1 bn share repurchase.

Expected impact

likely modest upward pressure as the market prices in the earnings beat and buyback authorization

Evidence & confidence

The beat on EPS and revenue, together with a large share repurchase, are fresh, material facts that typically drive short‑term buying. Guidance is only slightly under consensus, limiting upside.

Market effects

Sector

Strengthens the diabetes‑monitoring device sector, supporting peers with similar product pipelines.

Regional

Positive for U.S. medical‑device stocks; limited impact outside North America.

Global

Reinforces investor confidence in wearable glucose monitoring technology worldwide.

Counterpoint

What could challenge this read

Guidance slightly below consensus may signal slower growth, suggesting caution despite the beat.

Key entities

  • company
    Dexcom Inc.

    Medical device maker of continuous glucose monitoring systems.

  • executive
    Jake Leach

    President and CEO of Dexcom, quoted in the release.

Read at source← All news

StoryDexcom reports Q3 2026 earnings beating estimates and raises full-year revenue outlook

Also covered by

3 outlets

Related articles

NOV 2
$DXCMHighAI 8/10

Dexcom lifts 2026 revenue outlook after positive Q3

Dexcom reported Q3 revenue of $1.3bn, up 11% YoY, and raised its 2026 revenue outlook to $5.2bn-$5.25bn. US revenue grew 14% YoY, while international revenue increased 5%. The company also made progress in rolling out its G7 15 Day CGM and improving its Stelo app. Dexcom's stock rose 2% to $81.52 on 30 October.

finance.yahoo.com2 min
NOV 1
$DXCMHighAI 8/10

DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory

DexCom reported Q3 revenue of $1.34B, beating estimates by 1.2%, and adjusted EPS of $0.73, beating by 8.3%. The company raised its full-year revenue guidance to $5.23B. DexCom saw U.S. market share gains, driven by clinical trial results and new product launches, including the G7 15 Day system and a redesigned Stelo app. Operational improvements and expansion into international markets also contributed to margin growth.

finance.yahoo.com2 min
OCT 30
$DXCMHighAI 8/10

Dexcom (DXCM) Q3 2026 Earnings Call Transcript

Dexcom (DXCM) reported Q3 2026 revenue growth of 11%, with U.S. revenue up 14%. The company gained market share, driven by strong CGM demand and positive clinical trial results. Dexcom expects CMS to announce a type 2 non-insulin coverage decision this year, supported by the CONNECT study. The company also launched a redesigned Stelo app and advanced the rollout of its G7 15 Day system.

finance.yahoo.com2 min
OCT 30
$DXCMMed

Raymond James raises DexCom stock price target to $97 on U.S. growth

Raymond James raised its price target for DexCom (DXCM) to $97 from $94, citing strong U.S. sales growth and margins. The stock trades at $79.93, with a Fair Value estimate suggesting upside. DexCom announced a new share buyback program and raised its full-year outlook, reporting Q3 2026 earnings of $0.73 per share and revenue of $1.34 billion, both exceeding expectations.

investing.com1 min
OCT 30
$DXCMHighAI 8/10

DexCom Inc (DXCM) Q3 2026 Earnings Call Highlights: Double-Digit Revenue Growth

DexCom Inc (DXCM) reported Q3 2026 earnings, highlighting double-digit revenue growth and strong margins. CEO Jake Leach and CFO Jereme Sylvain addressed pricing, Medicare coverage, and product launches. The company raised full-year 2026 revenue guidance to $5.20B-$5.25B and adjusted EBITDA margin guidance to ~32%. DexCom also announced a European distributor acquisition, expected to close in 2027.

finance.yahoo.com2 min